ALNY
Alnylam Pharmaceuticals Inc
224.40$
+0.2%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -108.3% | – | – | -64.8% | -316.6% | – | – | +111.5% | -49.7% | -56.9% | +6.8% | – | |
| – | -42.7% | +0.3% | +11.0% | +224.6% | -142.2% | – | -3.2% | -1.0% | -2.2% | +0.3% | +2.6% | – | |
| – | -34.3% | +8.0% | +96.9% | -48.7% | +100.1% | -38.1% | +96.9% | -3.1% | -33.8% | -2.1% | +23.5% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -73.4% | -1,885.9% | – | – | -341.5% | – | – | -508.7% | – | – | – | – | |
| – | -10.4% | -15.3% | -38.2% | -47.7% | +116.9% | -1.4% | +59.3% | -15.0% | +91.8% | -6.3% | +58.8% | – | |
| – | +2,135.7% | -71.9% | – | -189.1% | +74.9% | – | -224.3% | – | -107.4% | -31.3% | +1,323.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +18.4% | -26.3% | +354.8% | -21.9% | -69.8% | +42.2% | +21.9% | -934.0% | – | -65.3% | +46.9% | – | |
| – | -158.7% | – | – | -54.2% | -201.9% | – | +74.7% | +302.7% | -56.0% | -67.7% | -599.0% | – | |
| – | -113.2% | – | – | -66.0% | -362.6% | – | – | +124.5% | -55.2% | -65.3% | -16.5% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.